Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer

• Status: NOT_YET_RECRUITING
• Trial end date: 2032-01-01

Summary

The use of neoadjuvant immuno-chemotherapy could improve survival outcomes of patients eligible for sequential radio-chemotherapy comparing to the benefit already obtained with maintenance immunotherapy.

• Phase: PHASE2

Details

• Lead Sponsor: Intergroupe Francophone de Cancerologie Thoracique
• Treatments: Carboplatin; cemiplimab; Maintenance; Paclitaxel